All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2022-12-01T10:39:43.000Z

ASH 2022 abstracts: What’s hot in GvHD?

By Alice Hyde, Ella Dixon
Featured
Ali Bazarbachi
Amin Alousi
Arnon Nagler
Attilio Olivieri
Bipin Savani
Florent Malard
Frederic Baron
Grzegorz Basak
Hildegard Greinix
Mohamad Mohty
Mutlu Arat
Robert Zeiser
Steven Pavletic
Takanori Teshima
Zinaida Peric
Dec 1, 2022
Share:

Bookmark this article

To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub Steering Committee members provided their recommendations for the top presented abstracts in GvHD.

Additional publications about the latest data presented at ASH 2022 can be found here.

GvHD prophylaxis and early phase trials

LBA-4

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

111

Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: ​

Mechanism of Success of the ABA2 Agvhd Prevention Trial 

572

Ruxolitinib in Pediatric Patients with Treatment-Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study 

573

Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial 

574

Addition of Ruxolitinb to Corticosteroids As First-Line Therapy for High-Risk Acute Graft Versus Host Disease in Allogeneic Peripheral Blood Stem Cell Transplantation 

770

Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy 

771

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309 

772

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis 

773

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant 

 

Novel therapies

112

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France ​

769

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide 

774

RGI-2001 Infusion for Prevention of Acute Gvhd after Allogeneic Hematopoietic Cell Transplantation 

 

Risk stratification

113

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis ​


ASH2022 abstracts

To download this document, click below.

Download here

More about...
Acute graft-versus-host diseaseASH 2022Chronic graft-versus-host diseaseGraft-versus-host diseaseSteroid-refractory GvHD

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
8 votes - 27 days left ...

Related articles

Add bookmark

Supportive care provision for patients with GvHD

During the GvHD Hub Steering Committee Meeting in October 2023, key opinion leaders met to discuss supportive care provisions for patients with GvHD. The recorded discussion was chaired by Professor...

Dec 18, 2023
Add bookmark

Supportive care provision for patients with GvHD

During the GvHD Hub Steering Committee Meeting in October 2023, key opinion leaders met to discuss supportive care provisions for patients with GvHD....

Dec 18, 2023
Add bookmark

How should duration of response be defined?

During the GvHD Hub Steering Committee meeting on April 5, 2022, key opinion leaders met to debate how duration of response should be defined. The recorded discussion was chaired by Mohamad Mohty and...

Jul 22, 2022
Add bookmark

How should duration of response be defined?

During the GvHD Hub Steering Committee meeting on April 5, 2022, key opinion leaders met to debate how duration of response should be defined. The recorded...

Jul 22, 2022

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox